《共同促进结直肠癌精准治疗》医疗培训课件.pptxVIP

共同促进结直肠癌精准治疗 于 丁 教授 湖北省肿瘤医院 来自全国20多个个省市的100多名同道济济一堂，交流ASCO/WCGIC新进展 3 RAS是目前mCRC唯一确定的生物标志物，西妥昔单抗是肠癌唯一符合精准治疗的药物 HR=0.69 (0.54–0.88) p=0.0024 Δ = 8.2 months HR=0.796 (0.67–0.95) p=0.0093 HR=0.878 (0.77–1.00) p=0.0419 Δ = 3.5 months Δ = 1.3 months 1. Van Cutsem E, et al. J Clin Oncol 2011;29:2011–2019;2. Van Cutsem E, et al. J Clin Oncol 2015;33:692–700;3. Douillard J-Y, et al. N Engl J Med 2013;369:1023–1034; 4. Erbitux SmPC June 2014; 5. Vectibix SmPC February 2015. Figure adapted from data from Van Cutsem E, et al.2 Cetuximab and panitumumab are approved in patients with